Stockscreener 앱 받기
79.29
1.50%
1.17
시간 외 거래:
79.40
0.11
+0.14%
Merck Co Inc 주식(MRK)의 최신 뉴스
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer - Insider Monkey
Ascentage Pharma to Participate in Evercore China Biotech Summit - GlobeNewswire Inc.
N.J.-based Merck announces $3B in cost cutting measures including layoffs - NJ.com
Oppenheimer Considers Merck & Co. (MRK) Agreement as Strong Endorsement for Veeva’s Vault CRM - Insider Monkey
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns - Benzinga
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Call Transcript - Insider Monkey
Merck Layoffs Announced: Axing Both Land and Labor In One Fell Swoop - The HR Digest
Merck & Co Inc (MRK) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE - insights.citeline.com
Merck Stock Is Almost A Classical Benjamin Graham Investment - Seeking Alpha
Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed - TradingView
Merck will lay off employees and shed some real estate to cut $3 billion in costs - MSN
Earnings call transcript: Merck Q2 2025 beats EPS, stock dips on revenue miss - Investing.com
Why Is Merck Stock Falling On Tuesday?Merck & Co (NYSE:MRK) - Benzinga
MRK Earnings: Merck & Co Q2 adj. profit drops on lower sales - AlphaStreet
Merck Cuts $3 Billion in Costs as Keytruda Reign Nears End - MSN
Merck posts Q2 earnings miss, unveils cost-cutting initiative - Proactive financial news
Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms - Bloomberg.com
Merck & Co., Inc. Reports Mixed Second-Quarter 2025 Results - Tokenist
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results - BioSpace
Merck & Co. Announces New Restructuring Program - TipRanks
Merck in Charts: KEYTRUDA sales surge 9% Y/Y, GARDASIL dips 54% in Q2 (NYSE:MRK) - Seeking Alpha
Merck plans $3B annual cost cuts as Keytruda faces patent cliff (MRK:NYSE) - Seeking Alpha
Merck & Co Inc. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Merck Q2 Earnings Preview: What to expect? - Seeking Alpha
How To Earn $500 A Month From Merck Stock Ahead Of Q2 Earnings - Benzinga
Merck & Co., Inc. Earnings Preview: Insights and ExpectationsNews and Statistics - IndexBox
Leerink Partners Slashes PT on Merck & Co. (MRK) to $92 From $115 - Insider Monkey
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup - Insider Monkey
UBS Bullish on Merck (MRK) Following Verona Pharma Purchase - MSN
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production - MSN
Companion Animal Medicine Market Key Players AnalysisMerck & - openPR.com
Merck Announces Fourth-Quarter 2025 Dividend - BioSpace
Merck Declares $0.81 Per Share Q4 Dividend: Key Dates and Payment Details Revealed - Stock Titan
Lobbying Update: $4,980,000 of MERCK & CO INC lobbying was just disclosed - Nasdaq
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects? - 富途牛牛
Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times
Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - MSN
MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest
Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey
2.38%
자본화:
|
볼륨(24시간):